Unicycive Therapeutics UNCY 深 沪
等待开盘 01-30 09:30:00 美东时间
6.67
-0.350
-4.99%
华盛通- 最 高7.00
- 今 开6.87
- 成交量 174.30万股
- 最 低 6.41
- 昨 收 7.02
- 总市值 1.43亿
- 52周最高 11.00
- 市盈率 静 --
- 换手率 8.11%
- 52周最低 3.71
- 委 比 77.76%
- 总股本 2149.14万
- 历史最高 87.30
- 量 比 3.18
- 振 幅 8.40%
- 历史最低 2.02
- 每 手 1
- 风险率 0.93%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Unicycive resubmits NDA for hyperphosphatemia asset
Unicycive Therapeutics (UNCY) has resubmitted an NDA to the US FDA for its candidate for hyperphosphatemia in individuals with chronic kidney disease, oxylanthanum carbonate. In late June, the company...
2025-12-30 05:25
Unicycive Therapeutics Has Resubmitted Its 505(b)(2) New Drug Application To FDA For Oxylanthanum Carbonate For Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis
The NDA for OLC was resubmitted based on continued progress by the original third-party manufacturing vendor in resolving FDA-cited deficiencies and demonstrating inspection readiness. Unicycive previously discussed
2025-12-29 20:08
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
Unicycive Therapeutics has resubmitted its NDA for oxylanthanum carbonate (OLC) to the FDA for treating hyperphosphatemia in CKD dialysis patients. The resubmission follows progress by the third-party manufacturer to regain FDA compliance. With adequate funding, the company aims to complete the regulatory process and bring the treatment to market soon. The NDA resubmission aligns with a Type A meeting with the FDA in September 2025, addressing pr...
2025-12-29 12:05
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
Unicycive Therapeutics, Inc., a biotechnology company focused on developing treatments for kidney diseases, announced that its CEO, Shalabh Gupta, M.D., will participate in two investor events in December. The events include a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, and a virtual presentation by Noble Capital Markets on December 10, 2025. Links to the webcasts will be available on the company's we...
2025-11-25 12:05
Unicycive Therapeutics Doubles Stock Sale Agreement
Unicycive Therapeutics ( ($UNCY) ) just unveiled an announcement. On November 1...
2025-11-15 06:34
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
Unicycive Therapeutics announced its Q3 2025 financial results and business updates, highlighting its plan to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year-end. OLC showed significant reduction in pill burden for hyperphosphatemia patients, with 7x lower volume and 2x fewer pills compared to existing treatments. The company ended Q3 with $42.7 million in cash, expecting runway into 2027. R&D expenses decreased s...
2025-11-12 12:05
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
2025-10-30 14:22
Unicycive Therapeutics Plans To Resubmit NDA For Oxylanthanum Carbonate By Year-End
Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the Company or Unicycive), today announced an update from its meeting with the
2025-10-28 19:10
Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End
<p>Unicycive Therapeutics announced plans to resubmit its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) by year-end following a constructive FDA meeting. The company aims for a PDUFA date in early 2026. With $42 million in cash, it expects to maintain operations into 2027. OLC, an investigational phosphate binder, offers potential advantages in reducing pill burden for dialysis patients with hyperphosphatemia. The company remains fo...
2025-10-28 11:05
UNCY Lawsuit Alert! Class Action Lawsuit Against Unicycive Therapeutics
Aclass actionlawsuit was filed againstUnicycive Therapeutics ...
2025-09-30 21:18
